Possibilities for treating aspirin-i lesions of the stomach and duodenum in patients with chronic coronary heart disease

To evaluate possibilities of aspirin-induced gastroduodenopathy treatment in the patients with chronic ischemic heart disease by means of applying the internal endogenous prostaglandins stimulant.
 Material and methods. 340 patients suffering from chronic coronary heart disease and receiving a long-term acetylsalicylic acid (ASA) therapy were examined on the base of the cardiovascular care unit of The Nizhny Novgorod Regional Clinical Hospital named after N.A. Semaschko. There were evaluated frequency, nature and severity of the aspirin-induced gastroduodenopathy. The patients with coronary heart disease and aspirin-induced gastroduodenopathy were divided in two groups. In the first group of patients there was applied rebamipide therapy (in a single daily dose 300 mg) in combination with the proton pump inhibitor (PPI) — pantoprazole. In the second group there was applied only pantoprazole therapy. For the purpose of specification of AIG pathogenetic mechanisms development, all the examined chronic coronary heart disease cases were tested on the prostaglandin E2 (PGE2) level in blood serum before the therapy beginning and after the treatment. The control group was formed of chronic coronary heart disease patients showing no AIG evidence. Statistical processing of the received data was fulfilled with the program «Statistika 10.0».
Results. AIG was registered in 15% out of 340 chronic coronary heart disease patients. According to the endoscopic examination erosive disease of the body and antrum prevailed among the patients. The PGE2 level in the blood serum was significantly lower (р = 0,00087) in these patients in comparison with the control group. In association with PPI and rebamipide mixed therapy, esophagogastroduodenoscopy results showed no pathological findings in gastrointestinal mucosa and statistically significant (р = 0,00067) blood serum PGE2 level growing in all the treated patients. As a result of exclusive PPI therapy there was marked positive dynamics in endoscopic view in 19 out of 25 patients and a tendency to normalization of PGE2 level in the blood serum. However, PGE2 level growing was insignificant.
Conclusion. The presented research demonstrates the possibility of AIG treatment with the use of internal endogenous prostaglandins stimulant — rebamipide in complex with proton pump inhibitor PPI therapy.

1. Karpov Yu.A., Kukharchuk V.V., Lupanov V.P. et al. Diagnosis and treatment of chronic ischemic heart disease. Kardiologicheskij vestnik. 2015;10(3):3–33. (in Russian)

2. Seliverstova D.V., Evsina O.V. Acetylsalicylic acid in primary prevention of Cardiovascular diseases. Serdce: zhurnal dlya praktikuyushchih vrachej. 2014;79(5):298–302. doi: 10.18087/rhj.2014.5.1987.

3. Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. doi: 10.1016/S0140-6736(09)60503-1.

4. Nedogoda S.V. Aspirin as a «Gold standart» in cardiovascular prevention. Rossijskij kardiologicheskij zhurnal. 2010;(3):86–9.

5. Komarov A.L. Gastroenteropathies associated with acetylsalicylic acid: how to improve safety of therapi. Racional’naya farmakoterapiya v kardiologii. 2009;5(4):65–72.

6. Lanas A., Perez-Aisa M.A., Feu F. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal antiinflammatory drug use. Am. J. Gastroenterol. 2005;8:1685–93. doi: 10.1111/j.1572-0241.2005.41833.x.

7. Minushkina A.O. Safety problems when using acetylsalicylic acid preparations for the prevention of cardiovascular complications. Serdce: zhurnal dlya praktikuyushchih vrachej. 2014;77(3):173–8.

8. Orlova A.Ya. Some issues of the appointment of acetylsalicylic acid in clinical practice. Arterial’naya gipertenziya. 2015;21(5):536–44. doi: https://doi.org/10.18705/1607-419X-2015-21-5-536-544.

9. Endo H., Sakai E., Higurashi T. et al. Differences in the severity of small bowel mucosal injury based in the type of aspirin as evaluated by capsule endoscopy. Dig. Liver. Dis. 2012;44(10):833–8. doi: 10.1016/j.dld.2012.05.016.

10. Miamoto M., Haruma K., Okamoro T. et al. Continuous proton pump inhibitor treatment decreases upper gastrointestinal bleeding and related death in rural area in Japan. J. Gastroenterol. Hepatol. 2012;27(2):372–7. doi: 10.1111/j.1440-1746.2011.06878.x.

11. Fontes-Carvalho R., Albuquerque A., Araujo C. et al. Omeprasole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patient after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur. J. Gastroenterol. Hepatol. 2011;23:396–404. doi: 10.1097/MEG.0b013e3283460110.

12. Park S.H., Cho C.S., Lee O.Y. et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J. Clin. Biochem. Nutr. 2007;2:148–55. doi: 10.3164/jcbn.40.148.

13. Kazyulin A.N., Goncharenko A.Yu., Mayev I.V. The use of rebamipide as a gastroprotective and anti-inflammatory drug for NSAIDs-gastropathies. Lechebnoe delo. 2016;3:50–8.

14. Abe N., Funato H., Hirata A. et. al. Evaluation of gastric mucosal injury model animals of rebamipide formulation-study of therapeutic equivalence. Yakugaku Zasshi. 2016;136(4):677–684. doi: 10.1248/yakushi.15-00014.

15. Shakhmatova O.O., Komarov A.L. Acetylsalicylic acid. Latest news about doses, efficacy and safety of long-term treatment. Atmosfera. Novosti kardiologii. 2011;3:2–10.

16. Brzozowski Т., Konturek P.C., Konturek S.J. et al. Classic NSAID and selective COX-1 and COX-2 inhibition in healing chronic gastric ulcers. Microsc. Res. Tech. 2001;53:343–53. doi: https://doi.org/10.1002/jemt.1102